we develop manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates we address these risks through a risk management program that includes the use of derivative financial instruments we operate the program pursuant to documented corporate risk management policies we do not enter derivative transactions for speculative purposes gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures furthermore we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positionsour currency risk consists primarily of foreign currency denominated firm commitments forecasted foreign currency denominated intercompany and thirdparty transactions and net investments in certain subsidiaries we use both nonderivative primarily european manufacturing operations and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates we had currency derivative instruments outstanding in the contract amount of 4100 billion as of december 31 2016 and 3547 billion as of december 31 2015 we recorded 199 million of other assets and 26 million of other liabilities to recognize the fair value of these derivative instruments as of december 31 2016 as compared to 237 million of other assets and 23 million of other liabilities as of december 31 2015 a ten percent appreciation in the us dollars value relative to the hedged currencies would increase the derivative instruments fair value by 257 million as of december 31 2016 and 155 million as of december 31 2015 a ten percent depreciation in the us dollars value relative to the hedged currencies would decrease the derivative instruments fair value by 223 million as of december 31 2016 and by 189 million as of december 31 2015 any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset liability or forecasted transaction resulting in minimal impact on our consolidated statements of operationsour interest rate risk relates primarily to us dollar borrowings partially offset by us dollar cash investments we have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates we have no interest rate derivative instruments outstanding as of december 31 2016 as of december 31 2016 4670 billion of our outstanding debt obligations was at fixed interest rates representing approximately 85 percent of our total debtsee note e  fair value measurements to our 2016 consolidated financial statements contained in item 8 of this annual report for further information regarding our derivative financial instruments 57report of independent registered public accounting firmthe board of directors and shareholders of boston scientific corporationwe have audited the accompanying consolidated balance sheets of boston scientific corporation as of december 31 2016 and 2015 and the related consolidated statements of operations comprehensive income loss stockholders equity and cash flows for each of the three years in the period ended december 31 2016 our audits also included the financial statement schedule listed in the index at item 15a2 these financial statements and schedule are the responsibility of the companys management our responsibility is to express an opinion on these financial statements and schedule based on our auditswe conducted our audits in accordance with the standards of the public company accounting oversight board united states those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement an audit includes examining on a test basis evidence supporting the amounts and disclosures in the financial statements an audit also includes assessing the accounting principles used and significant estimates made by management as well as evaluating the overall financial statement presentation we believe that our audits provide a reasonable basis for our opinionin our opinion the financial statements referred to above present fairly in all material respects the consolidated financial position of boston scientific corporation at december 31 2016 and 2015 and the consolidated results of its operations and its cash flows for each of the three years in the period ended december 31 2016 in conformity with us generally accepted accounting principles also in our opinion the related financial statement schedule when considered in relation to the basic financial statements taken as a whole presents fairly in all material respects the information set forth thereinwe also have audited in accordance with the standards of the public company accounting oversight board united states boston scientific corporations internal control over financial reporting as of december 31 2016 based on criteria established in internal controlintegrated framework issued by the committee of sponsoring organizations of the treadway commission 2013 framework and our report dated february 23 2017 expressed an unqualified opinion thereons ernst amp young llpboston massachusettsfebruary 23 2017  58